BioSpace News Archive

Santen Pharmaceutical Co., Ltd. and Eyevance Holdings LLC announced that Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, and Eyevance Holdings LLC entered into a share purchase agreement where Santen Holdings U.S. Inc. acquires all of outstanding shares of Eyevance Pharmaceuticals Holdings Inc..

Prytime Medical Devices, Inc. introduced its latest aortic occlusion catheter, the ER-REBOA™ PLUS this week at the American Association for the Surgery of Trauma (AAST) Annual Meeting.

University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is the cause of COVID-19.

ContinuumRx, a provider of home infusion and specialty pharmacy services based in Birmingham, Alabama, announced today that Keith Hartman has been named Chief Executive Officer.

ProtoLytic, an innovative healthcare software development company, announced the appointment of Tedd Thomas as Chief Revenue Officer.

In lieu of an in-person update to the media, Dr. Theresa Tam , Canada’s Chief Public Health Officer, issued the following statement today: “There have been 138,803 cases of COVID-19 in Canada , including 9,188 deaths. 88% of people have now recovered. Labs across Canada tested an average of 47,111 people daily over the past week

Grant enables the development of new detection technologies for DJ-1 in biofluids to create a new biomarker for the potential early diagnosis and tracking of the progression of Parkinsons disease

Aktana, the pioneer in intelligent engagement for the life sciences industry, introduces its next-generation Contextual Intelligence Engine to optimize interactions with healthcare professionals (HCPs). Aktana’s Contextual Intelligence Engine combines advanced artificial intelligence technologies and human intelligence to align life sciences commercial teams’ engagement with HCPs across channels. The global AI healthcare market is set to hit

Brain Mapping Foundation (BMF) and Society for Brain Mapping and Therapeutics (SBMT) have been on the forefront of combatting COVID-19 with their enormous network of scientists, physicians, and engineers worldwide.

Searchlight Pharma is pleased to confirm the commercial availability in Canada of Addyi® (flibanserin) for the treatment of Hypoactive Sexual Desire Disorder (HSDD).